Thursday, December 08, 2016 9:11:35 PM
A relatively worst case scenario (but not really) would be Merck only paying for the cost of Keytruda. Still not bad if ONCS can get good interim results by mid 2018 IMO.
Let's say for a moment the registration trial is a success. Merck will fully step in then, IMO. Again, PD has said quite a few times that they have no intention of going to market alone and I trust him when he says that. Anyway, after success in melanoma, do you think Merck will wait for ONCS to take another 2 years for an additional indication and so on? I don't think so. I think FDA approval in melanoma combo will open the floodgates to multiple combo trials which ONCS will not be able to manage on its own. That's when the real reward may come in for investors, either through a buyout or a bigger collaboration. Of course the registration trial will need to produce statistically significant results. Hence the risk.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM